Study Summary
This trial is testing a new type of immune therapy to see if it is safe and effective against a brain tumor called ependymoma.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
3 Primary · 12 Secondary · Reporting Duration: Up to 15 years from the initiation of protocol treatment
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Treatment (HER2 CAR T cells), Phase I Arm
1 of 2
Treatment (HER2 CAR T cells), Surgical Arm
1 of 2
Experimental Treatment
50 Total Participants · 2 Treatment Groups
Primary Treatment: HER2 Specific CAR T Cell · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 1 - 22 · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What are the objectives of this experiment?
"The primary assessment over a 42-day period following the initial CAR T cell infusion is to record Patients who experience Dose-Limiting Toxicities (DLT). Secondary criteria for success include the Best Antitumor Response of Infused HER2 CAR T Cells in Surgical Arm and Phase I Arms, which are determined by measuring Complete Responses (CR) or Partial Responses (PR), as well asOverall Survival (OS) calculated from two years after protocol treatment begins." - Anonymous Online Contributor
Is enrollment for this experiment still possible?
"Affirmative. Clinicaltrials.gov has evidence to suggest that recruitment for this medical study, first uploaded on July 27th 2022, is still ongoing. The project requires 50 volunteers distributed across 5 sites." - Anonymous Online Contributor
What risks are associated with the use of HER2 Specific CAR T Cell therapy?
"Due to the fact that HER2 Specific CAR T Cell is in its initial testing stage, there are limited clinical findings verifying efficacy and safety. So, our team at Power provisionally scored it a 1 on the scale from 1-3." - Anonymous Online Contributor
How many individuals are partaking in this clinical investigation?
"Affirmative. According to the data available on clinicaltrials.gov, this clinical trial commenced recruitment activities on July 27th 2022 and is still active as of November 15th 2022. The study necessitates 50 participants from 5 distinct sites." - Anonymous Online Contributor
Are there any other sites participating in this experimental protocol within the city?
"This study is being administered at Pittsburgh Children's Hospital of UPMC, Cincinnati Children's Hospital Medical Center, and Ann & Robert H. Lurie Children's Hosptial in Chicago as well as five other clinical sites." - Anonymous Online Contributor
Is this research recruiting participants aged 70 or older?
"Eligibility for this medical experiment is only open to persons aged 1 year through 22 years old. Additionally, 47 clinical trials are available for minors and 10 such studies exist for seniors." - Anonymous Online Contributor
What criteria must a participant fulfill to be accepted into this research endeavor?
"Individuals diagnosed with ependymoma, aged between 1 and 22 years old, are welcome to apply for this clinical trial. Approximately 50 candidates need to be recruited in total." - Anonymous Online Contributor